Focus: Eli Lilly is a $34.1B revenue Big Pharma company headquartered in Indianapolis, IN with 43,000 employees specializing in biologics discovery across diabetes, oncology, neuroscience, and immunology.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Eli Lilly and Company to get notified when they start hiring — the background below is worth knowing for when they do.
Company's revenue engine at 59% concentration; GLP-1 agonist in peak commercial phase generating sustained high margins.
Help build intelligence for Eli Lilly and Company
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Eli Lilly and Company's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Next-generation dual GLP-1/GIP agonist with strong obesity label expansion potential; exclusivity protected until 2041.
CDK4/6 inhibitor in peak commercial phase with extended exclusivity to 2031; growing indication expansion potential.
Legacy insulin product approaching loss of exclusivity; represents declining revenue stream with generic competition risk.
Established osteoporosis agent nearing exclusivity loss; part of erosion risk portfolio.
RET inhibitor in early growth phase with long exclusivity runway; oncology precision medicine play expanding indications.
108 discontinued, 24 duplicate formulations not shown
+10 more products with revenue data
Ahead of Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Ahead of Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? Morningstar
Amazon GLP-1 Push Tests Eli Lilly Valuation And Growth Expectations - simplywall.st
Amazon GLP-1 Push Tests Eli Lilly Valuation And Growth Expectations simplywall.st
20 Biggest Healthcare Companies - Built In
20 Biggest Healthcare Companies Built In
Why You Should Not Worry About Eli Lilly (LLY) and Company’s Foundayo Treatment Prospects - Insider Monkey
Why You Should Not Worry About Eli Lilly (LLY) and Company’s Foundayo Treatment Prospects Insider Monkey
Pharma giant Eli Lilly reacts to counterfeit Mounjaro racket in Gurugram - ET BrandEquity
Pharma giant Eli Lilly reacts to counterfeit Mounjaro racket in Gurugram ET BrandEquity
Insilico Medicine and Eli Lilly and Company Partner on AI-Driven Drug Discovery - CDO Magazine
Insilico Medicine and Eli Lilly and Company Partner on AI-Driven Drug Discovery CDO Magazine
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
No active FDA warnings, WARN filings, or reported shortages indicate operational stability; however, patent cliff exposure (2028-2030) and revenue concentration create restructuring risk in medium term.
Recent peer-reviewed publications with author affiliations at this company
+10 more products
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo